MedPath

Gadoteric acid

Generic Name
Gadoteric acid
Brand Names
Dotarem
Drug Type
Small Molecule
Chemical Formula
C16H25GdN4O8
CAS Number
72573-82-1
Unique Ingredient Identifier
QVF9Y6955W

Overview

Gadoteric acid is a macrocycle-structured gadolinium-based MRI contrast agent. It is composed of the organic acid DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) used for its chelating properties, and gadolinium (Gd3+). As a paramagnetic molecule, gadoterate develops a magnetic moment when placed in a magnetic field. This magnetic moment enhances the relaxation rates of water protons in its vicinity, leading to an increase in signal intensity (brightness) of tissues. More specifically, it reduces the T1 relaxation time (and to some extent the T2 and T2* relaxation times) in NMR, which is the source of its clinical utility. Increased signal brightness allows it to be used in imaging of blood vessels and of inflamed or diseased tissue where the blood vessels become 'leaky'. Gadoteric acid, as the FDA approved product Dotarem, is indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity.

Background

Gadoteric acid is a macrocycle-structured gadolinium-based MRI contrast agent. It is composed of the organic acid DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) used for its chelating properties, and gadolinium (Gd3+). As a paramagnetic molecule, gadoterate develops a magnetic moment when placed in a magnetic field. This magnetic moment enhances the relaxation rates of water protons in its vicinity, leading to an increase in signal intensity (brightness) of tissues. More specifically, it reduces the T1 relaxation time (and to some extent the T2 and T2* relaxation times) in NMR, which is the source of its clinical utility. Increased signal brightness allows it to be used in imaging of blood vessels and of inflamed or diseased tissue where the blood vessels become 'leaky'. Gadoteric acid, as the FDA approved product Dotarem, is indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity.

Indication

Gadoteric acid is indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity.

Associated Conditions

No associated conditions information available.

FDA Approved Products

DOTAREM
Manufacturer:Guerbet LLC
Route:INTRAVENOUS
Strength:376.9 mg in 1 mL
Approved: 2023/01/10
NDC:67684-2001
Gadoterate Meglumine
Manufacturer:Fresenius Kabi USA, LLC
Route:INTRAVENOUS
Strength:376.9 mg in 1 mL
Approved: 2022/04/30
NDC:65219-088
DOTAREM
Manufacturer:Guerbet LLC
Route:Intravenous
Strength:376.9 mg in 1 mL
Approved: 2022/04/27
NDC:67684-2000
DOTAREM
Manufacturer:Guerbet LLC
Route:INTRAVENOUS
Strength:376.9 mg in 1 mL
Approved: 2023/01/10
NDC:67684-3001
gadoterate meglumine
Manufacturer:Slate Run Pharmaceuticals, LLC
Route:INTRAVENOUS
Strength:376.9 mg in 1 mL
Approved: 2025/04/16
NDC:70436-123

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath